Pamela Carroll is Chief Business Officer at Roivant Discovery, a biotechnology company pioneering a physics-driven approach to drug design that is tightly coupled to chemistry, biology, and computer simulations. Roivant Discovery was previously Silicon Therapeutics, a venture-backed private company, until its acquisition by Roivant Sciences. Previously, Pamela was SVP of Immuno-oncology at Genocea Biosciences where she spearheaded the development of vaccines and cell therapies. Prior to Genocea, Pamela held the position of Vice President at Janssen Oncology/Johnson and Johnson Innovation leading strategic partnerships, newco investments, and academic collaborations. Additionally, she successfully led drug discovery organizations in positions including Vice President of Roche Oncology Discovery and Head of Research at the Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Center and Harvard Medical School. Earlier in her career Pamela served as Director of Cancer Pathways at Merck Research Laboratories and as Senior Investigator in Applied Genomics at Bristol Myers Squibb. Pamela received a BS in Biology from Saint Michael’s College in Vermont, a PhD in Cell Biology from Stony Brook University, and completed a postdoctoral fellowship at Stanford University.
